Drug Profile
BT 5528
Alternative Names: BT-5528Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Class Antineoplastics; Auristatins; Bicyclic peptide drug conjugates; Bicyclic peptides; Drug conjugates; Immunotoxins; Peptides
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 29 Feb 2024 Bicycle Therapeutics has patent protection for BT 5558 for composition of matter, methods of use for Cancer before February 2024
- 14 Dec 2023 Efficacy and adverse events data from the phase I/II trial in Solid tumours released by Bicycle Therapeutics
- 07 Sep 2022 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Bicycle Therapeutics